US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Biofrontera Inc Warrant

0.0400

+0.007422.70%

Volume:3.00K

Turnover:118.08

Market Cap:- -

PE:- -

High:0.0401

Open:0.0399

Low:0.0300

Close:0.0326

Loading ...

Overview Company News Filings

Biofrontera Full Year 2024 Earnings: Misses Expectations

Simply Wall St.

Biofrontera Inc (BFRI) Q4 2024 Earnings Call Highlights: Record Revenue Growth Amidst Financial ...

Q4 2024 Biofrontera Inc Earnings Call

Thomson Reuters StreetEvents

Biofrontera Inc. Reports Record Fiscal Year 2024 Financial Results and Provides a Business Update

THOMSON REUTERS

Biofrontera Inc. Announces Completion of Patient Enrollment in Phase 3 Study of Ameluz® (aminolevulinic acid HCI) Topical Gel, 10% for the Treatment of Actinic Keratoses on the Extremities, Neck and Trunk

Biofrontera Inc. to Report Fourth Quarter and Full Year 2024 Financial Results on March 21, 2025

When Will Biofrontera Inc. (NASDAQ:BFRI) Turn A Profit?

Simply Wall St.

Biofrontera Inc. Announces Achievement of Key Milestone in Phase 3 Study of Ameluz®-Photodynamic Therapy (Pdt) in the Treatment of Superficial Basal Cell Carcinoma (Sbcc)

THOMSON REUTERS

Biofrontera Inc. to Present at The Benchmark Company's Upcoming Discovery One-on-One Investor Conference

Biofrontera Inc (BFRI) Q3 2024 Earnings Call Highlights: Strategic Advancements Amidst Revenue ...

Biofrontera Inc. (BFRI) Reports Q3 Loss, Lags Revenue Estimates

Biofrontera Inc. to Report Third Quarter Financial Results on November 13, 2024

Biofrontera Inc. Announces Highly Significant Results in Phase 3 Study of Ameluz®-Photodynamic Therapy (Pdt) Regarding the Treatment of Superficial Basal Cell Carcinoma (Sbcc)

THOMSON REUTERS

Biofrontera Inc. Announces Database Lock of Phase 3 Study of Ameluz®-Photodynamic Therapy (Pdt) in the Treatment of Superficial Basal Cell Carcinoma (Sbcc)

THOMSON REUTERS

Biofrontera Inc - Last Patient Follow-up Expected by Dec, FDA Submission Targeted for Q1 2025

THOMSON REUTERS

Biofrontera Inc - Data NOW Being Analyzed, Interim Results Expected November 2024

THOMSON REUTERS

Biofrontera Inc (BFRI) Q2 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic ...

FDA Approves Use of up to Three Tubes of Biofrontera Inc.’s Ameluz (Aminolevulinic Acid Hci) Topical Gel, 10% in One Treatment

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/BFRIW/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BFRIW","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BFRIW\",,,,,undefined,":{"symbol":"BFRIW","market":"US","secType":"STK","nameCN":"Biofrontera Inc Warrant","latestPrice":0.04,"timestamp":1746216000000,"preClose":0.0326,"halted":0,"volume":3002,"delay":0,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Pre-Mkt","change":0.0074,"latestTime":"05-05 06:56:51 EDT","open":0.0399,"high":0.0401,"low":0.03,"amount":118.080597,"amplitude":0.309816,"askPrice":0,"askSize":0,"bidPrice":0.0255,"bidSize":100,"shortable":3,"etf":0,"ttmEps":0,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1746451800000},"marketStatusCode":1,"adr":0,"listingDate":1635480000000,"exchange":"NASDAQ","adjPreClose":0.0399,"volumeRatio":0.7456903049897194},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BFRIW\",,,,,undefined,":{"symbol":"BFRIW","floatShares":0,"roa":"-35.18%","roe":"-325.31%","lyrEps":0,"volumeRatio":0.7456903049897194,"shares":0,"dividePrice":0,"high":0.0401,"amplitude":0.309816,"preClose":0.0326,"low":0.03,"week52Low":0.015,"pbRate":"0.00","psRate":"0.00","week52High":0.255,"institutionHeld":0,"latestPrice":0.04,"committee":1,"eps":0,"divideRate":0,"volume":3002,"delay":0,"ttmEps":0,"open":0.0399,"prevYearClose":0.0607,"prevWeekClose":0.04,"prevMonthClose":0.0399,"prevQuarterClose":0.0602,"fiveDayClose":0.0459,"twentyDayClose":0.076,"sixtyDayClose":0.06},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BFRIW\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2521176842","title":"Biofrontera Full Year 2024 Earnings: Misses Expectations","url":"https://stock-news.laohu8.com/highlight/detail?id=2521176842","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521176842?lang=en_us&edition=fundamental","pubTime":"2025-03-22 22:06","pubTimestamp":1742652418,"startTime":"0","endTime":"0","summary":"This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality.NasdaqCM:BFRI Earnings and Revenue Growth March 22nd 2025. All figures shown in the chart above are for the trailing 12 month  period. Revenue missed analyst estimates by 5.1%. Earnings per share  also missed analyst estimates by 6.1%.Looking ahead, revenue is forecast to grow 23% p.a. on average during the next 3 years, compared to a 8.4% growth forecast for the Pharmaceuticals industry in the US.The company's shares are down 7.1% from a week ago.Don't forget that there may still be risks. For instance, we've identified   3 warning signs for Biofrontera  that you should be aware of.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/biofrontera-full-2024-earnings-misses-140658190.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BFRI","BFRIW"],"gpt_icon":0},{"id":"2521292291","title":"Biofrontera Inc (BFRI) Q4 2024 Earnings Call Highlights: Record Revenue Growth Amidst Financial ...","url":"https://stock-news.laohu8.com/highlight/detail?id=2521292291","media":"GuruFocus.com","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521292291?lang=en_us&edition=fundamental","pubTime":"2025-03-22 15:01","pubTimestamp":1742626908,"startTime":"0","endTime":"0","summary":"Total Revenue : $12.6 million, an increase of 18.5% from Q4 2023.Total Revenue : $37.3 million, up 9.5% from 2023.Operating Expenses : $14.3 million, compared to $14.5 million in Q4 2023.Cost of Revenues : $5.3 million, compared to $5.4 million in Q4 2023.Cost of Revenues : $18.6 million, up from $17.4 million in 2023.Net Loss : $1.4 million or $0.19 per share, compared to net income of $3.5 million or $1.65 per share in Q4 2023.Net Loss : $17.8 million or $3.22 per diluted share, compared to $20.1 million or $13.02 per share in 2023.Adjusted EBITDA : Negative $15.3 million, compared to negative $19.5 million in 2023.Cash and Cash Equivalents : $5.9 million, up from $1.3 million at the end of 2023.Inventory : $6.6 million, down from $10.9 million at the end of 2023.GuruFocus has detected 2 Warning Signs with BFRI.Biofrontera Inc  achieved record sales of $37.3 million in 2024, marking an annual sales growth of 18.5% for Q4 and nearly 10% for the entire year.A: Eugene Frederick Leffler,","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/biofrontera-inc-bfri-q4-2024-070148824.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BFRIW","BFRI"],"gpt_icon":0},{"id":"2521295753","title":"Q4 2024 Biofrontera Inc Earnings Call","url":"https://stock-news.laohu8.com/highlight/detail?id=2521295753","media":"Thomson Reuters StreetEvents","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521295753?lang=en_us&edition=fundamental","pubTime":"2025-03-22 11:54","pubTimestamp":1742615667,"startTime":"0","endTime":"0","summary":"Hermann Luebbert; Executive Chairman of the Board, Chief Executive Officer; Biofrontera Inc. Good morning and welcome to the Biofrontera fourth quarter in fiscal 2024 Financial results and Business update conference call.  I would now like to turn the conference over to Andrew Barwicki, investor relations representative. Please go ahead.Yeah, thank you, and my thanks to everyone joining up this morning. On today's call, I'll provide an overview of our accomplishments throughout 2024 and how our initiatives and execution have resulted in a record sale here. Eugene Frederick Leffler, our CFO, will follow with a discussion on financial results, and then both of us will be available to answer questions after our prepared remarks. I am pleased","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/q4-2024-biofrontera-inc-earnings-035427246.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BFRI","BFRIW"],"gpt_icon":0},{"id":"2521886382","title":"Biofrontera Inc. Reports Record Fiscal Year 2024 Financial Results and Provides a Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2521886382","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521886382?lang=en_us&edition=fundamental","pubTime":"2025-03-21 20:00","pubTimestamp":1742558402,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250321:nTUA1HJZM8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BFRIW","BK4007","BFRI"],"gpt_icon":0},{"id":"2520670343","title":"Biofrontera Inc. Announces Completion of Patient Enrollment in Phase 3 Study of Ameluz® (aminolevulinic acid HCI) Topical Gel, 10% for the Treatment of Actinic Keratoses on the Extremities, Neck and Trunk","url":"https://stock-news.laohu8.com/highlight/detail?id=2520670343","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520670343?lang=en_us&edition=fundamental","pubTime":"2025-03-18 21:30","pubTimestamp":1742304600,"startTime":"0","endTime":"0","summary":"First US Phase 3 study of Photodynamic Therapy  to include neck, trunk and extremities. Protocol involves one or two PDT treatments using 1-3 tubes of Ameluz or vehicle gel over a surface area of up to 240 cm2. “We are thrilled to reach this pivotal stage in our clinical program,” said Dr. Hermann Luebbert, CEO and Chairman of Biofrontera Inc. “The successful enrollment of our last patient brings us one step closer to potentially offering an effective treatment option for patients with actinic keratoses on the extremities, neck and trunk. It marks a significant step in expanding the indications for Ameluz and further demonstrates our commitment to the development of PDT.”With enrollment complete, Biofrontera anticipates finishing the treatment phase of the study by September, 2025 and the follow-up phase by Q2 2026. Pending positive outcomes, the company plans t","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/biofrontera-inc-announces-completion-patient-133000923.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4107","HCI","BK4007","BFRI","BFRIW","PDT"],"gpt_icon":0},{"id":"2518966742","title":"Biofrontera Inc. to Report Fourth Quarter and Full Year 2024 Financial Results on March 21, 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2518966742","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518966742?lang=en_us&edition=fundamental","pubTime":"2025-03-11 22:00","pubTimestamp":1741701600,"startTime":"0","endTime":"0","summary":"Fourth Quarter and FY 2024 Financial Results and Business Update Conference Call","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/biofrontera-inc-report-fourth-quarter-140000911.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BFRIW","BFRI","BK4007"],"gpt_icon":0},{"id":"2513855274","title":"When Will Biofrontera Inc. (NASDAQ:BFRI) Turn A Profit?","url":"https://stock-news.laohu8.com/highlight/detail?id=2513855274","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513855274?lang=en_us&edition=fundamental","pubTime":"2025-02-22 20:57","pubTimestamp":1740229067,"startTime":"0","endTime":"0","summary":"Biofrontera Inc.  is possibly approaching a major achievement in its business, so we would like to shine some light on the company. Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. With the latest financial year loss of US$20m and a trailing-twelve-month loss of US$13m, the US$8.6m market-cap company alleviated its loss by moving closer towards its target of breakeven. As path to profitability is the topic on Biofrontera's investors mind, we've decided to gauge market sentiment. Below we will provide a high-level summary of the industry analysts’ expectations for the company.Consensus from 2 of the American Pharmaceuticals analysts is that Biofrontera is on the verge of breakeven. They anticipate the company to incur a final loss in 2025, before generating positive profits of US$884k in 2026. The company is therefore projected to breakeven just over a year from","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/biofrontera-inc-nasdaq-bfri-turn-125747076.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4588","BK4112","NDAQ","QLD","USAW.SI","BK4585","MNQmain","IE00BGHQF748.EUR","IE00B64PRP62.GBP","TQQQ","BFRIW","NQmain","TSYW.SI","USJW.SI","LU2210150020.SGD","QID","PSQ","IE00B3QW5Z07.USD","LU2210149790.SGD","SQQQ","BFRI",".IXIC","LU2095319765.USD","BK4007","NVIW.SI","IE00BKPKM429.USD"],"gpt_icon":1},{"id":"2501775813","title":"Biofrontera Inc. Announces Achievement of Key Milestone in Phase 3 Study of Ameluz®-Photodynamic Therapy (Pdt) in the Treatment of Superficial Basal Cell Carcinoma (Sbcc)","url":"https://stock-news.laohu8.com/highlight/detail?id=2501775813","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501775813?lang=en_us&edition=fundamental","pubTime":"2025-01-08 22:50","pubTimestamp":1736347800,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250108:nTUA6WMCJ5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BFRIW","BFRI","BK4007"],"gpt_icon":0},{"id":"2488594039","title":"Biofrontera Inc. to Present at The Benchmark Company's Upcoming Discovery One-on-One Investor Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2488594039","media":"ACCESSWIRE","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2488594039?lang=en_us&edition=fundamental","pubTime":"2024-12-04 00:00","pubTimestamp":1733241600,"startTime":"0","endTime":"0","summary":"WOBURN, MA / ACCESSWIRE / December 3, 2024 / Biofrontera Inc.  , a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy , today announced it will be presenting at The Benchmark Company's 13th Annual Discovery One-on-One Investor Conference to be held Wednesday, December 11th, 2024 at the New York Athletic Club in New York City.The conference offers emerging growth and dynamic publicly traded companies access to institutional and individual investors in a unique one-on-one format during which Biofrontera will be participating in one-on-one meetings with investors and analysts throughout the day.Biofrontera Inc. is a U.S.-based biopharmaceutical company specializing in the treatment of dermatological conditions with a focus on PDT. The Company commercializes the drug-device combination Ameluz with the RhodoLED lamp series for PDT of Actinic Keratosis , pre-cancerous skin lesions which may progress to invasive skin cancers1. The Company p","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/PFJRH16xceH_cOOcsPIYjw--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/accesswire.ca/76b73e1af1285930cde94d0663b67002","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/PFJRH16xceH_cOOcsPIYjw--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/accesswire.ca/76b73e1af1285930cde94d0663b67002"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/biofrontera-inc-present-benchmark-companys-160000083.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BFRIW","BK4007","BFRI","PDT"],"gpt_icon":0},{"id":"2483314253","title":"Biofrontera Inc (BFRI) Q3 2024 Earnings Call Highlights: Strategic Advancements Amidst Revenue ...","url":"https://stock-news.laohu8.com/highlight/detail?id=2483314253","media":"GuruFocus.com","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483314253?lang=en_us&edition=fundamental","pubTime":"2024-11-15 15:12","pubTimestamp":1731654776,"startTime":"0","endTime":"0","summary":"For the complete transcript of the earnings call, please refer to the full earnings call transcript.Biofrontera Inc  reported a significant increase in the total number of Ameluz tubes ordered, alongside a reduction in costs.The company improved its FDA label, allowing the use of up to three tubes of Ameluz per treatment, enhancing flexibility for healthcare providers.Outstanding clinical results were achieved for a new indication, with a high degree of statistical significance in the superficial BCC phase three study.The launch of the RDO LED XL lamp has been successful, with 105 new lamps installed in the first three quarters of 2024.Revenues in the third quarter were impacted by delayed shipments due to Hurricane Milton, affecting growth figures.The net loss for the third quarter of 2024 was $5.7 million, although this was an improvement from the previous year.Adjusted EBITDA for the third quarter was negative $4.6 million, reflecting higher general and administrative costs.GuruFocu","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/biofrontera-inc-bfri-q3-2024-071256402.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BFRI","BFRIW"],"gpt_icon":0},{"id":"2483550860","title":"Biofrontera Inc. (BFRI) Reports Q3 Loss, Lags Revenue Estimates","url":"https://stock-news.laohu8.com/highlight/detail?id=2483550860","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483550860?lang=en_us&edition=fundamental","pubTime":"2024-11-14 08:10","pubTimestamp":1731543002,"startTime":"0","endTime":"0","summary":"Biofrontera Inc.  came out with a quarterly loss of $0.86 per share versus the Zacks Consensus Estimate of a loss of $0.73. This compares to loss of $4.64 per share a year ago. These figures are adjusted for non-recurring items.Biofrontera Inc. , which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $9.01 million for the quarter ended September 2024, missing the Zacks Consensus Estimate by 18.15%. This compares to year-ago revenues of $8.9 million. The company has not been able to beat consensus revenue estimates over the last four quarters.Biofrontera Inc. Shares have lost about 66% since the beginning of the year versus the S&P 500's gain of 25.5%.While Biofrontera Inc. Has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zac","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/nxwFIPS2ImeTQYZMYlnAgg--~B/aD02MDA7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/1a018a29aef5adbf5b4319f32058e209","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/nxwFIPS2ImeTQYZMYlnAgg--~B/aD02MDA7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/1a018a29aef5adbf5b4319f32058e209"],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/biofrontera-inc-bfri-reports-q3-001002761.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BFRIW","BFRI"],"gpt_icon":0},{"id":"2480839940","title":"Biofrontera Inc. to Report Third Quarter Financial Results on November 13, 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2480839940","media":"ACCESSWIRE","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2480839940?lang=en_us&edition=fundamental","pubTime":"2024-11-01 23:55","pubTimestamp":1730476500,"startTime":"0","endTime":"0","summary":"WOBURN, MA / ACCESSWIRE / November 1, 2024 / Biofrontera Inc.  , a biopharmaceutical company specializing in the development and commercialization of PDT, announces it will report financial results for the three and nine months ended September 30, 2024 on Wednesday, November 13, 2024. The results will be released after the market close on Wednesday, Nov 13 and the company will host a conference call on Thursday, November 14 at 10:00am Eastern Time.Biofrontera Inc. Third Quarter 2024 Financial Results and Business Update Conference Call. Webcast | Third Quarter 2024 Financial Results and Business Update Conference Call. Biofrontera is a U.S.-based biopharmaceutical company specializing in the treatment of dermatological conditions with a focus on PDT. The Company commercializes the drug-device combination Ameluz with the RhodoLED lamp series for PDT of Actinic Keratosis, pre-cancerous skin lesions which may progress to invasive skin cancers1. The Company performs clinical trials to exte","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/PFJRH16xceH_cOOcsPIYjw--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/accesswire.ca/76b73e1af1285930cde94d0663b67002","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/PFJRH16xceH_cOOcsPIYjw--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/accesswire.ca/76b73e1af1285930cde94d0663b67002"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/biofrontera-inc-report-third-quarter-155500583.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4007","BFRIW","BFRI"],"gpt_icon":0},{"id":"2479360380","title":"Biofrontera Inc. Announces Highly Significant Results in Phase 3 Study of Ameluz®-Photodynamic Therapy (Pdt) Regarding the Treatment of Superficial Basal Cell Carcinoma (Sbcc)","url":"https://stock-news.laohu8.com/highlight/detail?id=2479360380","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479360380?lang=en_us&edition=fundamental","pubTime":"2024-10-31 22:32","pubTimestamp":1730385120,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241031:nTUA5SVC6R:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BFRIW","BK4007","BFRI"],"gpt_icon":0},{"id":"2475539871","title":"Biofrontera Inc. Announces Database Lock of Phase 3 Study of Ameluz®-Photodynamic Therapy (Pdt) in the Treatment of Superficial Basal Cell Carcinoma (Sbcc)","url":"https://stock-news.laohu8.com/highlight/detail?id=2475539871","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2475539871?lang=en_us&edition=fundamental","pubTime":"2024-10-14 22:30","pubTimestamp":1728916200,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241014:nTUA1CNX2Z:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BFRI","BFRIW","BK4007"],"gpt_icon":0},{"id":"2475067398","title":"Biofrontera Inc - Last Patient Follow-up Expected by Dec, FDA Submission Targeted for Q1 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2475067398","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2475067398?lang=en_us&edition=fundamental","pubTime":"2024-10-14 22:30","pubTimestamp":1728916200,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241014:nTUA1CNX2Z:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BFRI","BFRIW","BK4007"],"gpt_icon":0},{"id":"2475039806","title":"Biofrontera Inc - Data NOW Being Analyzed, Interim Results Expected November 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2475039806","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2475039806?lang=en_us&edition=fundamental","pubTime":"2024-10-14 22:30","pubTimestamp":1728916200,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241014:nTUA1CNX2Z:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","BFRI","BFRIW"],"gpt_icon":0},{"id":"2474822786","title":"Biofrontera Inc (BFRI) Q2 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic ...","url":"https://stock-news.laohu8.com/highlight/detail?id=2474822786","media":"GuruFocus.com","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2474822786?lang=en_us&edition=fundamental","pubTime":"2024-10-10 06:29","pubTimestamp":1728512970,"startTime":"0","endTime":"0","summary":"Revenue: $7.8 million for Q2 2024, a 34% increase from $5.8 million in Q2 2023.Total Operating Expenses: $12.9 million for Q2 2024, down from $14.5 million in Q2 2023.SG&A Expenses: $7.9 million for Q2 2024, reduced from $11.5 million in Q2 2023.Net Loss: $257,000 for Q2 2024, compared to $9.8 million in Q2 2023.Adjusted EBITDA: Negative $4.7 million for Q2 2024, compared to negative $7.9 million in Q2 2023.First Half Revenue: $15.8 million for the first half of 2024, an 8% increase from $14.6 million in the first half of 2023.First Half Net Loss: $10.7 million for the first half of 2024, compared to $17.3 million in the first half of 2023.Accounts Receivable: Reduced to $3.5 million as of June 30, 2024, from $5.2 million as of December 31, 2023.Shareholders' Equity: Increased to $10.9 million as of June 30, 2024.GuruFocus has detected 3 Warning Signs with BFRI.Biofrontera Inc  strengthened its balance sheet by paying down all outstanding debt in the second quarter.Despite improvements","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/biofrontera-inc-bfri-q2-2024-222930282.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BFRI","BFRIW"],"gpt_icon":0},{"id":"2473219177","title":"FDA Approves Use of up to Three Tubes of Biofrontera Inc.’s Ameluz (Aminolevulinic Acid Hci) Topical Gel, 10% in One Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2473219177","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2473219177?lang=en_us&edition=fundamental","pubTime":"2024-10-07 20:45","pubTimestamp":1728305100,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241007:nTUA3TMYRP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BFRIW","BFRI","BK4007"],"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":18,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/BFRIW\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"BFRIW\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"BFRIW\",market:\"US\",delay:false,,,undefined,":{}}}